Date: 2025/05/18 - 16:31
Semaglutide, available under the brand names Ozempic and Wegovy, may help decrease the risk of major adverse cardiovascular events after just six months of starting the medication, a new study indicates.
Date: 2025/05/13 - 23:32
First-generation GLP-1 weight-loss drugs can help reduce the risk of obesity-related cancers, new research shows. Liraglutide, exenatide, and dulaglutide were 41% more effective at preventing obesity-related cancers.